bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
288 hedge funds and large institutions have $8.48B invested in bluebird bio in 2018 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 108 increasing their positions, 99 reducing their positions, and 54 closing their positions.
17% more call options, than puts
Call options by funds: $177M | Put options by funds: $151M
9% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 99
1% more capital invested
Capital invested by funds: $8.41B → $8.48B (+$72.3M)
0.03% more ownership
Funds ownership: 8.25% → 8.28% (+0.03%)
6% less funds holding
Funds holding: 307 → 288 (-19)
31% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 54
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$340M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$226M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$149M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$96.6M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$78.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$59M |
| 2 |
Millennium Management
New York
|
-$58.8M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$31.9M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$29M |
| 5 |
Citigroup
New York
|
-$28.4M |
BLUE Hedge Fund Activity: Q3 2018 in Review
288 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2018, worth a combined $8.48B — up 0.86% from $8.41B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of BLUE and 37 opened new positions — a net loss of 17 holders — while 99 trimmed existing stakes and 108 added.
The largest buyer was Capital International Investors, adding an estimated $340M. The largest seller was Goldman Sachs, cutting an estimated $59M.
- 288 institutional investors held bluebird bio (BLUE) as of Q3 2018, down from 307 in Q2 2018.
- Funds reported $8.48B of bluebird bio stock for Q3 2018, up 0.86% quarter-over-quarter.
- 37 funds opened new bluebird bio positions in Q3 2018 and 54 closed out, a net change of -17 holders.
- The largest bluebird bio buyer in Q3 2018 was Capital International Investors, an estimated $340M added.
- The largest bluebird bio seller in Q3 2018 was Goldman Sachs, an estimated $59M sold.
Based on aggregated 13F filings for Q3 2018.